Chinese Biotech Stocks Outshine Tech Rally on Robust Earnings

Bloomberg
04-01

Chinese biotechnology stocks rallied on Tuesday, driven by better-than-expected earnings from key players and investors seeking defensive sectors ahead of the looming US tariffs.

Shares of Akeso Inc., which shocked the pharmaceutical world last year when a study of its lung cancer drug showed to be more effective than Merck & Co Inc.’s blockbuster Keytruda, jumped as much as 16% to a record in Hong Kong. CSPC Pharmaceutical Group and Hutchmed China Ltd. rose more than 10% each.

The rally helped extend gains in a sector gauge traded in Hong Kong to about 35% this year, surpassing the tech index’s nearly 23% rise.

Hong Kong-listed firms including BeOne Medicines, Hutchmed, Innovent Biologics and Hansoh Pharmaceutical reported robust earnings, said Leslie Yang, a Bloomberg Intelligence analyst. “Hutchmed and Innovent have achieved profitability ahead of market expectations.”

Tuesday’s rally was also backed by an increase in licensing deals between Chinese firms and pharmaceutical majors, earning the sector the nickname “the supermarket,” where big pharma companies shop to fill pipeline gaps, Macquarie Capital’s Tony Ren and Candyce Gao wrote in a note.

Chinese biotech sector has delivered a robust performance so far in 2025, helped by on-track commercial progress, improved earnings visibility and flows from assets out-licensing, said Jialin Zhang, head of China health-care research at Nomura.

“Hong Kong biotech is getting better sentiment on acceleration trend of Chinese biotech companies out-licensing to multinational corporations,” Jefferies analyst Cui Cui said. Anticipation is also building for Akeso’s release of Harmoni-2 trial OS data at YE25, which is “the data of the year” in global biotech industry, the brokerage said.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10